ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
0
views
0
references
Top references
cited by
1
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
1,588
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Guidelines on long-acting injectable cabotegravir for HIV prevention
Author(s):
Publication date:
2022
Journal:
World Health Organization
Read this article at
ScienceOpen
Bookmark
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Tobacco Prevention & Cessation
Data availability:
Comments
Comment on this article
Sign in to comment
Similar content
1,588
ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long‐acting regimen for HIV treatment
Authors:
ViiV Healthcare
Long-acting cabotegravir + rilpivirine for hiv maintenance: flair week 48 results
Authors:
C. Orkin
,
JM Molina
,
J Lombaard
Pharmacokinetics of cabotegravir and rilpivirine long-acting injectables in HIV-infected individuals through 48 weeks in the FLAIR and ATLAS phase 3 studies
Authors:
P Patel
,
S. Ford
,
H Crauwels
…
See all similar
Cited by
1
Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study
Authors:
Beatriz Grinsztejn
,
Thiago Silva Torres
,
Brenda Hoagland
…
See all cited by